Literature DB >> 3669845

Temporalis muscle-galea flap in craniofacial reconstruction.

R L Arden1, R H Mathog, L M Thomas.   

Abstract

With the advent of increasing technological and surgical sophistication in craniofacial surgery, reconstructive efforts are challenged to provide a reliable means of compartmentalization. When dural integrity is compromised in the face of nasopharyngeal or paranasal communication, the risk of ascending infection and potential life-threatening meningitis mandate cranial and facial compartments, separated by sufficient and healthy soft tissues. This paper describes a method of providing pedicled soft tissue coverage and support for the contents of the anterior cranial fossa using a temporalis muscle-galea rotation flap. The vascularized myofascial tissues, capable of carrying skin and bone grafts, are well suited to cover and protect large areas of the skull base. Several cases are described to show the advantages and disadvantages of the technique.

Entities:  

Mesh:

Year:  1987        PMID: 3669845     DOI: 10.1288/00005537-198711000-00017

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  4 in total

1.  The lateral skull base: a vascular perspective with clinical implications.

Authors:  A K Gadre; M J O'leary; R Zakhary; F H Linthicum; W F House
Journal:  Skull Base Surg       Date:  1991

2.  Role of bone graft in reconstruction of skull base defect: is a bone graft necessary.

Authors:  Y Yamamoto; H Minakawa; T Yoshida; H Igawa; T Sugihara; T Ohura; K Nohira
Journal:  Skull Base Surg       Date:  1993

3.  Experience with 24 cases of reconstructive anterior skull base surgery: classification and evaluation of postoperative facial appearance.

Authors:  Y Yamamoto; H Minakawa; K Kawashima; T Sugihara; S Fukuda; Y Sawamura; A Watanabe; K Nohira
Journal:  Skull Base Surg       Date:  2000

4.  Microvascular craniofacial reconstruction in cancer patients.

Authors:  M J Miller; M A Schusterman; G P Reece; S S Kroll
Journal:  Ann Surg Oncol       Date:  1995-03       Impact factor: 5.344

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.